Disc Medicine, Inc. $IRON Shares Bought by Armistice Capital LLC

Armistice Capital LLC boosted its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 14.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 499,391 shares of the company’s stock after acquiring an additional 63,391 shares during the period. Armistice Capital LLC’s holdings in Disc Medicine were worth $39,657,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. RA Capital Management L.P. raised its holdings in Disc Medicine by 25.3% in the 4th quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock valued at $156,925,000 after acquiring an additional 399,026 shares during the last quarter. Vanguard Group Inc. boosted its position in Disc Medicine by 22.1% during the 4th quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock worth $140,371,000 after purchasing an additional 319,621 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Disc Medicine by 28.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company’s stock worth $134,839,000 after buying an additional 371,576 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Disc Medicine by 110.0% in the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after buying an additional 828,248 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Disc Medicine by 13.6% in the 4th quarter. State Street Corp now owns 1,187,991 shares of the company’s stock valued at $94,338,000 after purchasing an additional 142,394 shares in the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Stock Performance

NASDAQ IRON opened at $70.21 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00. The company’s fifty day moving average is $68.44 and its two-hundred day moving average is $71.93. Disc Medicine, Inc. has a 52-week low of $40.00 and a 52-week high of $99.50. The firm has a market capitalization of $2.68 billion, a price-to-earnings ratio of -10.61 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.03). Equities research analysts forecast that Disc Medicine, Inc. will post -6.74 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on IRON shares. Wedbush restated an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a research note on Wednesday, June 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research report on Monday, April 20th. Truist Financial decreased their price objective on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating for the company in a report on Friday, February 27th. Morgan Stanley raised their target price on shares of Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday. Finally, Wall Street Zen upgraded shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Disc Medicine presently has a consensus rating of “Moderate Buy” and a consensus target price of $105.80.

Insider Activity

In related news, CFO Jean M. Franchi sold 6,257 shares of Disc Medicine stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total transaction of $433,234.68. Following the completion of the transaction, the chief financial officer directly owned 64,333 shares of the company’s stock, valued at $4,454,416.92. This trade represents a 8.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider William Jacob Savage sold 5,731 shares of Disc Medicine stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $66.38, for a total transaction of $380,423.78. Following the transaction, the insider directly owned 79,480 shares of the company’s stock, valued at $5,275,882.40. This represents a 6.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 12,388 shares of company stock valued at $841,258 over the last three months. 3.76% of the stock is currently owned by insiders.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.